Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.

Abstract:

BACKGROUND:Data from CHARM, a 56-week, randomized controlled trial of adalimumab for patients with moderately to severely active Crohn's disease (CD), were used to evaluate outcomes of adalimumab dosage adjustment. METHODS:Patients randomized to blinded adalimumab 40 mg every other week (EOW) in CHARM were the focus of the analysis. At ≥12 weeks, patients with flares or lack of response versus baseline (including patients who responded and then lost response) could move sequentially to open-label (OL) adalimumab EOW and then to OL adalimumab weekly. RESULTS:Of 260 patients randomized to adalimumab EOW, 140 (54%) continued blinded EOW therapy and 120 (46%) moved to OL therapy. Of patients on OL therapy, 49 (19%) continued EOW therapy and 71 (27%) moved to weekly therapy; 36 (14%) completed the trial on weekly therapy. Of 71 patients on weekly therapy, 37% achieved clinical remission (Crohn's Disease Activity Index [CDAI] <150), 58% achieved CR-100 (CDAI decreased ≥100 points), and 63% achieved CR-70 (CDAI decreased ≥70 points). Of the 49 patients who remained on OL EOW therapy, 39% achieved clinical remission, 59% achieved CR-100, and 63% achieved CR-70. In a logistic regression, greater baseline CDAI predicted changing to weekly therapy. A model of dosage-adjustment cost indicated a modest per-patient drug-acquisition cost increase ($574 over yearly EOW dosing cost [$22,518]). CONCLUSIONS:Of patients randomized to blinded EOW therapy, 19% moved to OL EOW therapy and 27% moved to OL weekly therapy for flares or lack of response versus baseline. Weekly therapy was associated with clear clinical benefits and a small cost increase.

journal_name

Inflamm Bowel Dis

authors

Sandborn WJ,Colombel JF,Schreiber S,Plevy SE,Pollack PF,Robinson AM,Chao J,Mulani P

doi

10.1002/ibd.21328

subject

Has Abstract

pub_date

2011-01-01 00:00:00

pages

141-51

issue

1

eissn

1078-0998

issn

1536-4844

journal_volume

17

pub_type

杂志文章,随机对照试验
  • On the role of ischemia in the pathogenesis of IBD: a review.

    abstract::Inflammatory bowel disease (IBD) is a chronic intestinal disorder comprising 2 distinct but often overlapping diseases: Crohn's disease and ulcerative colitis. Although much research to identify the etiology of IBD has focused on genetic constitution, infectious causes, and immune dysregulation, its exact cause and pa...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21061

    authors: Ibrahim CB,Aroniadis OC,Brandt LJ

    更新日期:2010-04-01 00:00:00

  • Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.

    abstract:BACKGROUND:Mesalazine preparations are widely used to treat mild to moderately severe ulcerative colitis (UC). We compared once-daily administration of oral mesalazine in patients with quiescent UC with the established 3-times-daily prescription, assessing the efficacy and safety of each method in maintaining remission...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/MIB.0b013e318286fa3d

    authors: Watanabe M,Hanai H,Nishino H,Yokoyama T,Terada T,Suzuki Y

    更新日期:2013-07-01 00:00:00

  • Pancreas duct abnormalities in patients with ulcerative colitis: a magnetic resonance pancreatography study.

    abstract:BACKGROUND:The presumed etiology and prevalence of pancreatic abnormalities in patients with ulcerative colitis (UC) have been controversial. We conducted a controlled (cross-sectional) study of patients with UC compared with non-UC controls to determine the prevalence of pancreatic duct abnormalities in patients with ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000183419.17563.17

    authors: Toda N,Akahane M,Kiryu S,Matsubara Y,Yamaji Y,Okamoto M,Minagawa N,Ohgi K,Komatsu Y,Yahagi N,Yoshida H,Kawabe T,Ohtomo K,Omata M

    更新日期:2005-10-01 00:00:00

  • A Controlled Study of a Group Mindfulness Intervention for Individuals Living With Inflammatory Bowel Disease.

    abstract:BACKGROUND:This study aimed to evaluate the feasibility, acceptability, and effectiveness of a mindfulness-based intervention for patients with inflammatory bowel disease (MI-IBD). DESIGN:Treatment-as-usual control versus mindfulness-based stress reduction intervention. METHODS:Sixty patients participated in either t...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000629

    authors: Neilson K,Ftanou M,Monshat K,Salzberg M,Bell S,Kamm MA,Connell W,Knowles SR,Sevar K,Mancuso SG,Castle D

    更新日期:2016-03-01 00:00:00

  • Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

    abstract:Background:We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods:Retrospective review (May 2014-December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates we...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy171

    authors: Shmidt E,Kochhar G,Hartke J,Chilukuri P,Meserve J,Chaudrey K,Koliani-Pace JL,Hirten R,Faleck D,Barocas M,Luo M,Lasch K,Boland BS,Singh S,Vande Casteele N,Sagi SV,Fischer M,Chang S,Bohm M,Lukin D,Sultan K,Swamina

    更新日期:2018-10-12 00:00:00

  • Phenotype classification in IBD: Is there an impact on therapy?

    abstract::This review summarizes the current phenotypic classifications of inflammatory bowel disease (IBD) and outlines their implications for diagnosis, therapy, prognosis, clinical trial design, and genotype-phenotype correlations. ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20232

    authors: Walfish A,Sachar D

    更新日期:2007-12-01 00:00:00

  • Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study.

    abstract:Background:The diagnostic work-up of pediatric irritable bowel syndrome (IBS) and functional abdominal pain-not otherwise specified (FAP-NOS) commonly includes invasive tests for discrimination from inflammatory bowel disease (IBD). As this carries a high burden on patients, an ongoing need exists for development of no...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy151

    authors: Bosch S,van Gaal N,Zuurbier RP,Covington JA,Wicaksono AN,Biezeveld MH,Benninga MA,Mulder CJ,de Boer NKH,de Meij TGJ

    更新日期:2018-10-12 00:00:00

  • Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.

    abstract:BACKGROUND:Noninvasive, sensitive, and specific tools for early identification of chronic inflammatory bowel disease (IBD) are needed for clinical practice. The aim was to identify new noninvasive test combinations for characterization of IBD in children and adolescents by comparing serological responses to microbial a...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20535

    authors: Ashorn S,Honkanen T,Kolho KL,Ashorn M,Välineva T,Wei B,Braun J,Rantala I,Luukkaala T,Iltanen S

    更新日期:2009-02-01 00:00:00

  • Acute Colitis Drives Tolerance by Persistently Altering the Epithelial Barrier and Innate and Adaptive Immunity.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) has a remitting and relapsing disease course; however, relatively little is understood regarding how inflammatory damage in acute colitis influences the microbiota, epithelial barrier, and immune function in subsequent colitis. METHODS:Mice were administered trinitrobenzene ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz011

    authors: Wardill HR,Choo JM,Dmochowska N,Mavrangelos C,Campaniello MA,Bowen JM,Rogers GB,Hughes PA

    更新日期:2019-06-18 00:00:00

  • Malignancy and Mortality in Pediatric-onset Inflammatory Bowel Disease: A Systematic Review.

    abstract:Background:Cancer and death are the most severe outcomes that affect patients with inflammatory bowel disease (IBD). These outcomes are even more severe if they occur at a young age but are rare, even in the general population. We conducted a systematic review to provide an overview of all reported pediatric (PIBD) pat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1093/ibd/izx104

    authors: Aardoom MA,Joosse ME,de Vries ACH,Levine A,de Ridder L

    更新日期:2018-03-19 00:00:00

  • Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach.

    abstract:BACKGROUND:Disappearance of macroscopic mucosal inflammation predicts long-term outcome in Crohn's disease (CD). It can be assessed by ileocolonoscopy, which is, however, an invasive and expensive procedure. Disease activity indices do not correlate well with endoscopic activity and noninvasive markers have a low sensi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000436

    authors: Bodelier AG,Smolinska A,Baranska A,Dallinga JW,Mujagic Z,Vanhees K,van den Heuvel T,Masclee AA,Jonkers D,Pierik MJ,van Schooten FJ

    更新日期:2015-08-01 00:00:00

  • Characterization of single-nucleotide polymorphisms relevant to inflammatory bowel disease in commonly used gastrointestinal cell lines.

    abstract:BACKGROUND:The era of genome-wide association studies (GWAS) has led to the identification of many inflammatory bowel disease (IBD)-associated single-nucleotide polymorphisms (SNPs) with unknown function. The next step would be to identify the functional consequences of these polymorphisms in order to target them effic...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21043

    authors: Huebner C,Petermann I,Lam WJ,Shelling AN,Ferguson LR

    更新日期:2010-02-01 00:00:00

  • Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease.

    abstract:BACKGROUND:MicroRNAs (miRNAs) are dysregulated in the inflammatory bowel diseases, Crohn's disease (CD) and ulcerative colitis (UC), which arise due to dysfunctional host-microbe interactions and impairment of the barrier function of the intestine. Here, we sought to determine whether circulating miRNAs are biomarkers ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000285

    authors: Krissansen GW,Yang Y,McQueen FM,Leung E,Peek D,Chan YC,Print C,Dalbeth N,Williams M,Fraser AG

    更新日期:2015-03-01 00:00:00

  • Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis.

    abstract:BACKGROUND:Mucosal healing (MH) as a treatment target for ulcerative colitis is of growing interest because it is associated with improved clinical outcomes. However, the feasibility and probability of reaching MH in clinical practice is unknown. We therefore evaluated the feasibility of "treating to target" according ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000437985.00190.aa

    authors: Bouguen G,Levesque BG,Pola S,Evans E,Sandborn WJ

    更新日期:2014-02-01 00:00:00

  • Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis.

    abstract:BACKGROUND:Activation of cannabinoid (CB)(1) receptors results in attenuation of experimental colitis. Our aim was to examine the role of CB(2) receptors in experimental colitis using agonists (JWH133, AM1241) and an antagonist (AM630) in trinitrobenzene sulfonic acid (TNBS)-induced colitis in wildtype and CB(2) recept...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20960

    authors: Storr MA,Keenan CM,Zhang H,Patel KD,Makriyannis A,Sharkey KA

    更新日期:2009-11-01 00:00:00

  • Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: a prospective study.

    abstract:BACKGROUND:Long-term enteral nutrition may maintain clinical and endoscopic remission in patients with Crohn's disease (CD). The aim of this prospective study was to investigate the impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal tissue cytokines in patients with quiesce...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20238

    authors: Yamamoto T,Nakahigashi M,Saniabadi AR,Iwata T,Maruyama Y,Umegae S,Matsumoto K

    更新日期:2007-12-01 00:00:00

  • Antibiotic Use in Childhood and Adolescence and Risk of Inflammatory Bowel Disease: A Case-Control Study in the UK Clinical Practice Research Datalink.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) causes serious morbidity and disability, and the incidence is increasing. The disease etiology is not well understood, though inflammatory reactions after antibiotic exposure may be associated with development of IBD. We investigated the association between IBD and prior anti...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz137

    authors: Troelsen FS,Jick S

    更新日期:2020-02-11 00:00:00

  • Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing.

    abstract:BACKGROUND:Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy is effective in treating some Crohn's disease (CD) patients and protects mice from colitis induced by dextran sulfate sodium (DSS) administration. However, its mechanisms of action remain elusive. We hypothesized that GM-CSF affects intestinal...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21072

    authors: Bernasconi E,Favre L,Maillard MH,Bachmann D,Pythoud C,Bouzourene H,Croze E,Velichko S,Parkinson J,Michetti P,Velin D

    更新日期:2010-03-01 00:00:00

  • Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease.

    abstract::Chemokines, a large family of small chemoattractive cytokines, and their receptors play an integral role in the regulation of the immune response and homeostasis. The ability of chemokines to attract specific populations of immune cells sets them apart from other chemoattractants. Chemokines produced within the gastro...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20480

    authors: Zimmerman NP,Vongsa RA,Wendt MK,Dwinell MB

    更新日期:2008-07-01 00:00:00

  • Thromboembolism in pediatric inflammatory bowel disease: systematic review.

    abstract:BACKGROUND:Several studies suggest an increased risk of venous and arterial thromboembolism (TE) in adults with inflammatory bowel disease (IBD) compared to the general population. We performed a systematic review of studies on incidence and characteristic of TE in children with IBD. METHODS:We searched Medline, LILAC...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21563

    authors: Lazzerini M,Bramuzzo M,Maschio M,Martelossi S,Ventura A

    更新日期:2011-10-01 00:00:00

  • Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.

    abstract:BACKGROUND:The risk of corticosteroid-associated adverse events can limit the use of systemic corticosteroids. Oral, topically acting, second-generation corticosteroids that deliver drug to the site of inflammation, and biologic therapies, are effective treatment alternatives. The aim of this review was to evaluate the...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000001261

    authors: Cross RK

    更新日期:2017-10-01 00:00:00

  • Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse.

    abstract:BACKGROUND:Inflammatory bowel diseases (IBD) are characterized by intermittent relapses, and their course is heterogeneous and unpredictable. Our aim was to determine the ability of protein, metabolite, or microbial biomarkers to predict relapse in patients with quiescent disease. METHODS:This prospective study enroll...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa183

    authors: Borren NZ,Plichta D,Joshi AD,Bonilla G,Sadreyev R,Vlamakis H,Xavier RJ,Ananthakrishnan AN

    更新日期:2020-09-18 00:00:00

  • Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.

    abstract:BACKGROUND:High doses of mesalazine usually result in an inconvenient dosage schedule and reduced compliance. The goal of this trial was to compare the effects of mesalazine 4 g daily given as prolonged-release granules in packets of 1 g with that of prolonged-release tablets of 0.5 g. METHODS:Two hundred twenty-seven...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00054725-200108000-00009

    authors: Farup PG,Hinterleitner TA,Lukás M,Hébuterne X,Rachmilewitz D,Campieri M,Meier R,Keller R,Rathbone B,Oddsson E

    更新日期:2001-08-01 00:00:00

  • Co-prescribing azathiopurine or 6-mercaptopurine and 5-aminosalicylate compounds in ulcerative colitis.

    abstract:BACKGROUND:A total of 254 senior consultant gastroenterologists with valid e-mail addresses were identified from the membership list of the British Society of Gastroenterology (BSG) 2007. METHODS:They were sent by e-mail a questionnaire which dealt with aspects of clinical practice and addressed cancer prevention in u...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20750

    authors: Mayberry H,Moshkovska T,Mayberry JF

    更新日期:2009-02-01 00:00:00

  • Intestinal interleukin-13 in pediatric inflammatory bowel disease patients.

    abstract:BACKGROUND:Interleukin-13 (IL-13) is a multifunctional cytokine whose net principle action is to diminish inflammatory responses. Dysregulation of IL-13 production has been proposed to contribute to intestinal inflammation in inflammatory bowel disease (IBD) patients. Previous studies implicate IL-13 in IBD pathogenesi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200409000-00014

    authors: Kadivar K,Ruchelli ED,Markowitz JE,Defelice ML,Strogatz ML,Kanzaria MM,Reddy KP,Baldassano RN,von Allmen D,Brown KA

    更新日期:2004-09-01 00:00:00

  • Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis.

    abstract:BACKGROUND:Mucosal healing in ulcerative colitis leads to a decreased need for medication and decreased risk of disease relapse and colectomy. Histological healing seems to improve the disease prognosis even further. An assessment of both endoscopic and histological mucosal healing requires endoscopy, and the need for ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000736

    authors: Theede K,Holck S,Ibsen P,Kallemose T,Nordgaard-Lassen I,Nielsen AM

    更新日期:2016-05-01 00:00:00

  • Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease.

    abstract:BACKGROUND:Microbiota is most likely essential in the pathogenesis of Crohn's disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majority of patients experience endoscopic recurrence in the neoterminal ile...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa107

    authors: Olaisen M,Flatberg A,Granlund AVB,Røyset ES,Martinsen TC,Sandvik AK,Fossmark R

    更新日期:2021-01-01 00:00:00

  • Enteric Infection in Relapse of Inflammatory Bowel Disease: The Utility of Stool Microbial PCR Testing.

    abstract:BACKGROUND:The similar presentations in relapse of inflammatory bowel disease (IBD) and enteric infection pose substantial barriers to diagnosis and treatment. The objective of this study was to investigate the incidence, etiology, predictors, and treatment of enteric infection in patients with IBD. METHODS:We reviewe...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000001097

    authors: Axelrad JE,Joelson A,Nobel YR,Lawlor G,Green PHR,Lichtiger S,Lebwohl B

    更新日期:2017-06-01 00:00:00

  • Retinoic acid contributes to the induction of IL-12-hypoproducing dendritic cells.

    abstract:BACKGROUND:Vitamin A is an important regulator of the human immune system, especially in the gut. Recent studies have revealed that retinoic acid (RA) in gut-associated dendritic cells (DCs) enhances the transforming growth factor (TGF)-beta-dependent conversion of naïve T cells into regulatory T (Treg) cells. Thus, RA...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20934

    authors: Wada Y,Hisamatsu T,Kamada N,Okamoto S,Hibi T

    更新日期:2009-10-01 00:00:00

  • Adalimumab therapy in Crohn's disease of the ileal pouch.

    abstract:BACKGROUND:Crohn's disease (CD) of the pouch can develop in patients with ileal pouch-anal anastomosis, resulting in significant morbidities, even pouch failure. The aim of this study was to evaluate short- and long-term outcome of adalimumab (ADA) in treating these patients. METHODS:A total of 48 patients who receive...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1002/ibd.22933

    authors: Li Y,Lopez R,Queener E,Shen B

    更新日期:2012-12-01 00:00:00